BMS' top drug faces patent challenge

Share this article:
The FDA approved a Canadian company’s application to produce a generic version of Bristol-Myers Squibb’s best-selling drug Plavix. The approval means generic maker Apotex could bring a generic form of the heart medication to market before a key Plavix patent expires in 2011. However, BMS and Sanofi-Aventis have sued Apotex over the validity and enforceability of the patent. A federal trial is scheduled for April. BMS “continues to believe that the patent is valid and that it is infringed, and with its alliance partner and patent-holder Sanofi-Aventis, is vigorously pursuing these cases,” BMS said in a statement. If the patent is held invalid, Apotex -- the first generic to file with the FDA -- stands to gain 180 days of generic market exclusivity on clopidogrel bisulfate. Plavix had 2005 US net sales of $3.2 billion.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.